Tag Archives: CRBP

Best Clean Energy Stocks To Watch Right Now

Related KOL Coal Companies Lobby For Clean Energy Subsidies Silver Shines Among 2016's Best ETFs

The VanEck Vectors Coal ETF (NYSE: KOL) was one of last year's best-performing non-leveraged exchange-traded funds for a simple reason: Of the two nominees for the U.S. presidency, one was vocal in her disdain for the coal industry while one vowed to restore the industry's lost jobs.

President Donald Trump, obviously, was the candidate that promised to restore coal country's lost glory and KOL responded. The ETF is doing so again this year with a year-to-date gain of almost 18 percent. That means KOL has nearly doubled in value over the past year. Still, there are ample indications that Trump's promises to coal miners will be hard to keep.

Best Clean Energy Stocks To Watch Right Now: Novo Nordisk A/S(NVO)

Advisors’ Opinion:

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Logan Wallace]

    Eagle Global Advisors LLC decreased its position in Novo Nordisk (NYSE:NVO) by 10.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,420 shares of the company’s stock after selling 15,550 shares during the period. Eagle Global Advisors LLC’s holdings in Novo Nordisk were worth $6,423,000 as of its most recent SEC filing.

  • [By Paul Ausick]

    Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.

  • [By Brian Orelli]

    Novo Nordisk (NYSE:NVO) continues its trend ofrelatively strong growth of its newer diabetes medications being offset by slower growth of older insulin drugs in the first quarter. Currency changes also negatively affected Novo’s revenue line, but that’s out of the company’s control.

  • [By Brian Orelli]

    Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.

Best Clean Energy Stocks To Watch Right Now: Adaptimmune Therapeutics plc(ADAP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.

  • [By Jon C. Ogg]

    Adaptimmune Therapeutics PLC (NASDAQ: ADAP) was started with a Market Perform at Wells Fargo.

    Aqua America Inc. (NYSE: WTR) was raised to Overweight from Equal Weight and the price target was raised to $36 from $33 (versus a $31.19 close) at Barclays.

Best Clean Energy Stocks To Watch Right Now: SITO Mobile, Ltd.(SITO)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Birchview Capital LP lifted its position in shares of SITO Mobile (NASDAQ:SITO) by 16.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 140,000 shares of the Wireless communications provider’s stock after acquiring an additional 20,000 shares during the period. SITO Mobile accounts for 0.4% of Birchview Capital LP’s portfolio, making the stock its 25th biggest holding. Birchview Capital LP’s holdings in SITO Mobile were worth $563,000 at the end of the most recent reporting period.

Best Clean Energy Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.

best stock for investment

When John Milligan speaks, people listen — especially if they’re Gilead Sciences (NASDAQ:GILD) shareholders.

The big biotech’s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on Wednesday. Milligan spoke directly to some of the most pressing concerns for Gilead shareholders. Here are three things he said that you’ll definitely want to know.

Image source: Getty Images.

1. We don’t know when the HCV business will bottom out.

The biggest worry on the minds of Gilead shareholders relates to the plunging sales for the biotech’s hepatitis C virus (HCV) franchise. John Milligan couldn’t — and didn’t — give any reason to think that there was a light at the end of the tunnel.

Milligan stated that Gilead doesn’t know if the HCV business will stabilize yet, and added that the company “might not know until it happens.” He said that his team initially thought that things might have stabilized last year, but “the dynamic didn’t play out as expected.”

best stock for investment: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:

  • [By Jim Robertson]

    Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).

best stock for investment: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

best stock for investment: E*TRADE Financial Corporation(ETFC)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Meanwhile, E*Trade (NASDAQ:ETFC) decided to split the difference. Effective March 13, E*Trade’s commission structure will get split in two. Base rate customers will see their commissions fall from $9.99 to $6.95 per trade, matching TD Ameritrade. However, E*Trade created a new structure for active traders, defined as those who execute 30 or more trades every three months. For those customers, E*Trade will have $4.95 per trade commissions, and options charges will fall by a third, to $0.50 per contract. CEO Karl Roessner said that although “an exceptional customer experience is far more important to traders and investors than price, with our new commission structure, we are able to reward our most active equity and derivative traders and investors.”

  • [By Jon C. Ogg]

    E*Trade Financial Corp. (NASDAQ: ETFC) was up another 1.6% at $32.97. Ithas a total market cap of $9 billion, and over the past five trading days the stock has gained 17%. Shares of Morgan Stanley (NYSE: MS) were last seen at $39.09, up 17% in the past fivetrading days. The market cap is$74.7 billion.

  • [By Chris Neiger]

    This article will walk your through all the steps for setting up an individual E*TRADE (NASDAQ:ETFC) brokerage account, which should only take about five to 10 minutes to complete. If you want to compare offers from other brokers, or view their features, check out ourbroker comparison page.

  • [By David Zeiler]

    In just three years, Robinhood’s customer base has surpassed that of entrenched online brokerage E*Trade Financial Corp. (Nasdaq: ETFC), which spent 35 years accumulating 3.6 million customers.

best stock for investment: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

best stock for investment: DBV Technologies S.A.(DBVT)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Monica Gerson]

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

    Northern Technologies International Corp (NASDAQ: NTIC) is projected to post its quarterly earnings.

  • [By Paul Ausick]

    DBV Technologies SA (NASDAQ: DBVT) dropped about 53.5% Monday to post a new 52-week low of $22.33 after closing at $48.07 on Friday. The stock’s 52-week high is $50.57. Volume of around 12 million was about 60 times the daily average. The French drug maker’s peanut allergy treatment failed a phase 3 study.

best stock for investment: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.